08. November 2017
Colon delivery systems for oral administration have grown in popularity since the 1990s, primarily because of the increasing incidence of inflammatory bowel disease (IBD) that has broadly been demonstrated to benefit from topical pharma- cological treatment.
07. October 2017
SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant β-lactamase enzyme designed to degrade β-lactam antibiotics administered intravenously, and thus prevent colon dysbiosis. Here we describe the development of the SYN-004 enteric coated pellet formulation, which has been tested in multiple clinical trials. Since the SYN-004 drug substance is a buffered liquid, several binder excipients in different ratios were tested to...
19. April 2017
Abstract Polymers are essential tools in the research and development of new therapeutic devices. The diversity and flexibility of these materials have generated high expectations in the composition of new materials with extraordinary abilities, especially in the design of new systems for the modified release of pharmaceutically active ingredients. The natural polymer rosin features moisture protection and pH-dependent behavior (i.e., it is sensitive to pH > 7.0), suggesting its possible use...
23. January 2017
Abstract Although the intestinal microbial community is still incompletely understood, there is strong evidence of the benefits of using probiotics to address some medical states or conditions. As a result, the probiotics oral supplements market has exploded during the last few years. However, while their sensitivity to gastric juices, acidic pH and bile is well known, most of these oral forms would not guarantee any survival of the strains in such conditions. In this work, we have studied the...
20. December 2016
Abstract Electrospraying is renowned for its simplicity and versatility, and which can effectively produce particles with well-controlled size, size distribution, particle shape, morphology and microstructure at the nano/microscale. In this study, coaxial electrospraying was used to investigate its feasibility for preparing nanoparticles made up of nanocrystals encapsulated within a polymer shell. Firstly, aqueous nanosuspensions of darunavir were prepared by wet media milling. Then the...
08. October 2016
Capsugel recently announced the launch of its Vcaps® Enteric capsules, a new functional capsule technology that achieves enteric protection and delayed release without the need for functional coating. The new capsules provide Capsugel’s customers with another solution for intrinsically enteric delivery, complementing the company’s enTRinsic™ Drug Delivery Technology launched in late 2015. Incorporating enteric polymers to form the primary capsule structure is a breakthrough in drug...
14. June 2016
Abstract Lansoprazole degrades rapidly in an aqueous solution at low pH values. Degradation rate increases at pH values below 4 .The aim of this study was development of enteric coated pellets containing Lansoprazole by an extrusion/ spheronization technique. Eight different formulations based on lactose and six different formulations based on mannitol, consisting of different portions of other excipients including sucrose, hydroxy propyl methyl cellulose, magnesium carbonate, and sodium lauryl...
25. January 2016
Gastro-resistant pellets were prepared by use of three different drug loading techniques (powder layering, solution layering and suspension layering) and two different enteric coating techniques (powder layering and suspension layering). Pellets produced by different layering techniques were compared in terms of morphological characteristcs, content of drug, release properties and stability. More
08. January 2016
DAV132 is a product designed as a prophylactic treatment intended to prevent the development of Clostridium difficile infection, by binding with and neutralizing common antibiotics in the gut. DAV132 more generally preserves the integrity of the intestinal microbiota during antibiotic cures.It has two clinical objectives: Prevent the occurrence and recurrence of C. difficile infections in high risk patients receiving antibiotics such as oral and parenteral fluoroquinolones and cephalosporins;...